Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Luksza M, Sethna ZM, Rojas LA, Lihm J, et al. Nature 2022 May 19. pii: 10.1038/s41586-022-04735.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Luksza M, Sethna ZM, Rojas LA, Lihm J, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 2022 May 19. pii: 10.1038/s41586-022-04735.
PMID: 35589842